• Gubra will host its Investor R&D Event in London on Oct. 27, 2026, at 13:00 GMT to present its 2030 strategy.
• The strategy targets 8-10 clinical-stage assets by 2030, with 1-2 proprietary drug development candidates nominated annually from 2030 onward.
• Presentations will cover GUB-UCN2's Phase 1/2a clinical program evaluating body composition, muscle volume and physical function.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.